v3.20.4
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 26, 2020
Apr. 09, 2020
Dec. 31, 2020
Jun. 28, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Sep. 29, 2020
Jul. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Finite-lived intangible assets, gross carrying amount $ 76,759,000,000     $ 76,759,000,000   $ 76,759,000,000 $ 75,058,000,000      
Research and development expenses [1]           9,405,000,000 8,394,000,000 $ 7,760,000,000    
Developed Technology Rights [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Finite-lived intangible assets, gross carrying amount [2] $ 73,545,000,000     73,545,000,000   73,545,000,000 72,449,000,000      
Collaborative Arrangement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development expenses [3]           $ 192,000,000 $ (104,000,000) $ (162,000,000)    
Collaborative Arrangement [Member] | CStone [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Committed investment from collaborator                 $ 200,000,000  
Ownership percentage 9.90%                  
Collaborative Arrangement [Member] | BioNTech [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Ownership percentage 2.50%                  
Collaborative Arrangement [Member] | Myovant [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum reimbursement due from collaborators, 2021   $ 100,000,000                
Maximum reimbursement due from collaborators, 2022   50,000,000                
Potential milestone payments   4,350,000,000                
Payment to collaborators       $ 650,000,000            
Milestone payments   200,000,000                
Collaborative Arrangement, tiered sales milestone payments   3,500,000,000                
Collaborative arrangement, milestone payment upon commercializing   50,000,000                
Research and development expenses   151,000,000                
Collaborative Arrangement [Member] | Myovant [Member] | Developed Technology Rights [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Finite-lived intangible assets, gross carrying amount   $ 499,000,000                
Collaborative Arrangement [Member] | BioNTech [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Committed investment from collaborator         $ 113,000,000         $ 50,000,000
Potential future milestone payments     $ 563,000,000              
Maximum potential cash payments     $ 748,000,000              
Percentage of costs to be reimbursed     50.00%              
Collaborative Arrangement [Member] | BioNTech [Member] | Research and Development Expense [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Payment to collaborators         $ 72,000,000          
[1] Exclusive of amortization of intangible assets, except as disclosed in Note 1L.
[2] The increase in the gross carrying amount primarily reflects the transfer of $600 million from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy, as well as a $499 million capitalized portion of an upfront payment to Myovant (see Note 2E) and an increase from a $200 million measurement period adjustment related to the acquisition of Array (see Note 2A), partially offset by a $528 million impairment of Eucrisa (see Note 4) and a $263 million impairment of certain generic sterile injectables acquired in connection with our acquisition of Hospira (see Note 4).
[3] Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements.